Cumberland Pharmaceuticals CPIX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Acetadote | $51.98K-22.0% | $66.67K-31.0% | $96.6K-50.1% | $193.55K+27.6% | $151.65K+277% | |
| Caldolor | $965.56K+7.7% | $896.71K+3.4% | $867.01K-45.4% | $1.59M+21.5% | $1.31M-4.8% | |
| Kristalose | $981.48K-68.6% | $3.12M+164% | $1.18M-57.1% | $2.75M-21.0% | $3.48M-20.4% | |
| Other revenue | $168.85K-8.5% | $184.62K-39.8% | $306.51K-37.8% | $492.39K-84.3% | $3.14M+1,348% | |
| Sancuso | $2.93M-11.0% | $3.29M+1.5% | $3.24M+3.9% | $3.12M+38.2% | $2.26M-5.2% | |
| Talicia | $1.92M— | —— | —— | —— | $0— | |
| Vibativ | $2.12M-24.5% | $2.81M+8.0% | $2.6M-3.8% | $2.7M-9.9% | $3M+44.8% | |
| Revenues, including adjustments by Product | ||||||
| Omeclamox-Pak | $1— | —— | -$3.13K-316% | -$752+86.0% | -$5.39K— | |
| RediTrex | -$489— | —— | $4.43K+36.7% | $3.24K+1,035% | -$347— | |
| Vaprisol | $517— | —— | $600+104% | -$14.62K-2,337% | -$600— | |
| Non-current inventories by Product | ||||||
| Acetadote | $23.14K-4.2% | $24.15K-65.3% | $69.62K— | $0-100% | $27.11K+13.3% | |
| Caldolor | $95.14K-15.6% | $112.76K-4.6% | $118.22K-27.4% | $162.89K-8.6% | $178.13K+130% | |
| Ifetroban | $40.88K0.0% | $40.88K-37.4% | $65.27K0.0% | $65.27K-56.6% | $150.4K-9.9% | |
| Kristalose | $2.26M+0.1% | $2.26M-4.3% | $2.36M-8.3% | $2.58M+6.4% | $2.42M-9.4% | |
| Sancuso | $615.87K-6.2% | $656.67K+130% | $285.15K-12.6% | $326.12K-15.3% | $384.91K-16.1% | |
| Vaprisol | $1.17M0.0% | $1.17M-0.1% | $1.17M0.0% | $1.17M0.0% | $1.17M0.0% | |
| Vibativ | $5.56M+13.8% | $4.88M+3.6% | $4.71M-5.4% | $4.98M-7.0% | $5.36M-13.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Cumberland Pharmaceuticals break its business down?
- Cumberland Pharmaceuticals (CPIX) reports revenue by product across 7 parts — Acetadote, Caldolor, Kristalose, Other revenue and Sancuso. Each is extracted from the segment footnotes and tracked over time.
- Where does Cumberland Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cumberland Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
